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KAREN ROTHENBERG’S (NOT SO)
SECRET ROLES AND
CONTRIBUTIONS
AT THE U.S. NATIONAL
INSTITUTES OF HEALTH
BENJAMIN E. BERKMAN, J.D., M.P.H.1,2, LAWRENCE C. BRODY, PH.D.2,
FRANCIS S. COLLINS, M.D., PH.D.2,3, AND ERIC D. GREEN, M.D., PH.D.2*
I. INTRODUCTION
As the metaphorical ‘center of the biomedical research universe,’ the U.S.
National Institutes of Health (NIH) regularly attracts the best and brightest minds
to help the agency pursue its mission – that is, “to seek fundamental knowledge
about the nature and behavior of living systems and the application of that
knowledge to enhance health, lengthen life, and reduce illness and disability.”
Achieving that mission in a socially responsible fashion depends on establishing
and maintaining a strong ethical and legal framework, something of profound
interest and concern to Professor Karen Rothenberg throughout her lengthy
career as a prominent legal scholar. It was, therefore, perhaps inevitable that NIH
and Karen would connect in highly productive and meaningful ways.
Karen’s interactions involved distinct parts of the NIH – specifically, the
National Human Genome Research Institute (NHGRI) and the Clinical Center’s
Department of Bioethics – and occurred intermittently over two decades, being
most intense during two periods. The first of these occurred in the 1990s, during
which Karen served as a valued ad hoc advisor to a then-adolescent NHGRI. At
that time, Francis Collins was the NHGRI Director, the field of genomics was
young and growing rapidly, and the Human Genome Project (HGP) was in full
swing. The second of these involved a more formal role from 2011 to 2015,
during which Karen served as a Special Advisor to the NHGRI Director (Eric
Green) and was also an Adjunct Faculty Member in the Clinical Center’s
© 2019 Benjamin E. Berkman, J.D., M.P.H., Lawrence C. Brody, Ph.D., Francis S.
Collins, M.D., Ph.D., and Eric Green, M.D., Ph.D. The opinions expressed herein
are the authors’ own and do not reflect the policies and positions of the National
Institutes of Health or the U.S. Department of Health and Human Services.
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Department of Bioethics. During both of these stints, Karen’s ability to straddle
the academic and policy divide allowed her to contribute as an advocate, advisor,
educator, scholar, and mentor.
II. ADVOCATE
Until the HGP came along, few if any scientific fields had sought to
anticipate the ethical, legal, and social consequences of their work, much less
analyze the societal implications and recommend legislative action – all long
before major advances from that work were realized. But starting in 1990, that is
precisely what the National Center for Human Genome Research (later renamed
NHGRI) did. At that time, an important issue emerged that, if not dealt with
effectively, could limit the societal benefit of genomics research: there needed to
be an effective way to prevent genetic discrimination.
To be successful, this effort required bold leadership. Karen’s vision,
passion, and deep expertise made her ideal for this role. As the Marjorie Cook
Professor of Law and Director of the Law and Health Care Program at the
University of Maryland Law School, she had the legal gravitas and personal
commitment to turn policy goals into concrete actions. As the National Action
Plan on Breast Cancer (NAPBC) came alongside as a natural partner in this
policy effort, Karen was appointed to NAPBC’s organizing body and quickly
became a leading voice at workshops and public discussions focused on avoiding
genetic discrimination. This led to her co-authoring a landmark 1995 Science
paper on genetic information and health insurance1 and subsequently a 1997
Science paper that provided specific recommendations to avoid workplace
discrimination on the basis of genetics.2
Those two articles became the foundation for everything that followed.
Though none of us thought that it would take more than a decade for effective
federal legislation to become law, we all celebrated in May 2008 when the
Genetic Information Nondiscrimination Act (GINA) was signed into law. Along
with an amazing team of scientists, advocates, legal scholars, and policy experts,
Karen had helped birth legislation with consequences so significant and profound
that Senator Edward Kennedy called GINA “the first major new civil rights bill
of the new century”.3

1. Kathy L. Hudson et al., Genetic Discrimination and Health Insurance: An Urgent Need for
Reform, 270 SCIENCE 391 (1995).
2. Karen H. Rothenberg, et al., Genetic Information and the Workplace: Legislative Approaches
and Policy Changes, 275 SCIENCE 1755 (1997).
3. Kathy L. Hudson et al., Keeping Pace with the Times – The Genetic Information
Nondiscrimination Act of 2008, 358 NEW ENGLAND J. MED. 2661 (2008).
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III. ADVISOR
Upon his appointment as NHGRI Director in 2009, Eric Green immediately
accelerated an ongoing round of strategic planning at the Institute. At several key
meetings related to the crafting of NHGRI’s 2011 strategic plan,4 Karen
contributed important and thoughtful input to intense discussions about the future
of NHGRI’s then-mature Ethical, Legal, and Social Implications (ELSI)
Research Program. Those contributions led to Karen playing a larger role
advising the new NHGRI Director on the reorganization and ‘modernization’ of
the Institute. Karen’s experience as the Dean of a major law school brought a
valued perspective, along with remarkable wisdom and sound judgment, to her
role as a Special Advisor.
While Karen’s advice related to multiple parts of NHGRI, her efforts were
most focused on the Institute’s Extramural Research Program (ERP). The ERP
oversees the funding of researchers outside of NIH and is responsible for roughly
three-quarters of the funds allocated to NHGRI by the U.S. Congress. For many
years, NHGRI’s ERP was laser-focused on the HGP, requiring a relatively
simple organizational structure. By the time of Karen’s arrival as a Special
Advisor (nearly a decade past the completion of the HGP), the breadth of
scientific areas covered by the NHGRI ERP had grown substantially. Managing
such a diverse program required a different organizational model. Ultimately, a
new configuration emerged that converted the NHGRI ERP from a single large
entity into a thematically defined four-division structure, one that then required
the appointment of four new division directors. Needless to say, this involved a
substantial amount of ‘change management,’ something that was greatly aided
by Karen’s sage advice and counsel.
Karen’s experience and expertise were particularly well-suited for helping
with one component of NHGRI’s ERP, the ELSI Research Program (which by
congressional mandate, is associated with 5% of the Institute’s research budget).
The Institute’s reorganization in 2012 provided the opportunity to elevate the
ELSI Research Program by making it the centerpiece of a new division (the
Division of Genomics and Society). Karen urged that the new Division embrace
a larger scope of activities beyond the ELSI Research Program, including a major
‘ELSI consultative role5 and opportunities for its staff to participate in scholarly
and outreach activities. With these added responsibilities, Karen recognized that
the Division would need ongoing advice over time. Towards that end, she helped
to establish a standing advisory body, the Genomics and Society Working Group;
the work of this group ensured that appropriate attention is paid to ELSI research
4. Eric D. Green et al., Charting a Course for Genomic Medicine from Base Pairs to Bedside, 470
NATURE 204 (2011).
5. Jean E. McEwen et al., The Ethical, Legal, and Social Implications Program of the National
Human Genome Research Institute: Reflections on an Ongoing Experiment, 15 ANNUAL REV. OF
GENOMICS AND HUM. GENET. 481 (2014).
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within NHGRI’s ever-growing research portfolio. Karen’s valued input also
aided the Division of Genomics and Society’s first permanent Director,
Lawrence Brody. Finally, Karen advocated for the Division to take a holistic
approach to its work. While ethical, legal, and social research can easily (and
often does) occupy three unconnected academic silos, Karen urged NHGRI to
join these silos and develop approaches for scholars in each of these areas to
work together. This highly collaborative approach to ELSI research represents a
lasting contribution of Karen’s advice.
IV. EDUCATOR
The University of Maryland Law School is renowned for its health law
program, but Karen was inspired to move beyond the normal law school
pedagogic focus on abstract legal theory by providing law students with an
opportunity to gain real-world experience in health policy at NHGRI.
Specifically, she developed the idea for an intensive workshop where students
would research and analyze a range of ethical, legal, and policy questions raised
by the increasing prevalence of human genome sequencing in research. Do
investigators have an ethical or legal duty to look for secondary findings? Does
the CLIA regulatory regime make sense in an era of genomic research? How
should institutional policies be structured to grapple with the challenges inherent
in obtaining informed consent to sequence an individual’s genome? How could
we strengthen laws protecting people against genetic discrimination? In close
consultation with NHGRI scientists and policy-makers, the students developed
meaningful insight about these (and other) real ethical and policy problems that
NHGRI was actively confronting. The intensive NHGRI policy experience was
so successful that Karen then created an ongoing NHGRI externship course
(which just completed its fourth year) in which law students are embedded in
various NHGRI groups for a semester. These innovative educational experiences
have been quite successful, but they were only possible because of Karen’s
unique position straddling the academic and policy worlds.
As another example of Karen’s creativity in expanding pedagogic
boundaries, she turned her passion for theater into a tool for teaching bioethics.
In collaboration with Lynn Bush (Columbia University), Karen recognized that
many of the ethical issues raised by genomics research and genomic medicine
have a substantial emotional component and require more than just detached
normative analysis. The duo wrote and staged innovative plays designed to
immerse an audience into the ethical debate, staging these plays at academic
conferences and local theaters. She even organized a conference at NHGRI
where playwrights were exposed to scientific and bioethical issues to serve as
inspiration in their own work. Karen and Lynn eventually wrote a book about
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this experience, which hopefully will be a useful tool as the scientific world
continues to grapple with difficult issues inherent to genomic advances.6
V. SCHOLAR AND MENTOR
As an Adjunct Faculty Member in the NIH Clinical Center’s Department
of Bioethics, Karen contributed her wisdom and expertise as a scholar in
residence and mentor. Through active discussion and collaboration, she helped
to sharpen her colleagues’ arguments. For example, Karen co-authored an article
with Department of Bioethics colleagues analyzing the liability issues raised by
the return genomic incidental findings to research participants.7 Published by the
highly ranked Georgetown Law Journal, this paper provided a framework for
courts to grapple with the potential onslaught of cases that inconsistent return of
results policies would likely provoke.
Through disagreement and combative collegiality, Karen’s advice and
critique of bioethics projects proved invaluable to strengthening colleagues’
scholarly work. As an example, one of us (BEB) has written extensively with
skepticism about the idea that people should have a strong right not to know
medically important genomic information about themselves.8 Karen
emphatically disagreed, arguing that individuals should be able to refuse
information about their genome, particularly information resulting from genetic
tests. The ensuing debates were instrumental for identifying and addressing
weaknesses in this controversial argument. While still on different sides of the
academic debate to this day, Karen’s unfettered willingness to engage in highlevel scholarly debate were undeniably helpful.
VI. A LEGACY OF VALUED CONTRIBUTIONS
Karen is a noted health law scholar and leader in the ELSI research
community, but her career has also included a less well-known but equally
important public service role as an advisor to NHGRI and NIH. In this role,
Karen has effectively drawn on her experience in legal academia to provide
invaluable insight to the emerging fields of genomics and genomic medicine.
Karen’s distinct combination of enthusiasm and wisdom helped to ensure that
genomics research was built upon a foundation of ethical and legal scholarship.
Her work continues to influence the field to this day.

6. KAREN H. ROTHENBERG AND LYNN BUSH, THE DRAMA OF DNA: NARRATIVE GENOMICS (2014).
7. Elizabeth R. Pike et al. Finding Fault?: Exploring Legal Duties to Return Incidental Findings in
Genomic Research, 102 GEO. L. J. 795 (2014).
8. Benjamin E. Berkman, Refuting the Right Not to Know, 19 J. Health Care L. & Pol’y 1 (2017).

